3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors

Patent metadata

Field	Value
Publication number	US-9630922-B2
Application number	US-201615130613-A
Country	US
Kind code	B2
Filing date	Apr 15, 2016
Priority date	Apr 17, 2015
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

First claim

The invention claimed is:

1. A compound of the Formula I:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer or thereof, wherein:
X 1 , X 2 , X 3 , X 6 , and X 7 are each independently —CR 1 R 2 —, —NR 3 —, —O—, —C(O)—, —SO 2 —, —S(O)—, or —S—;
X 4 and X 5 are each independently —CR 1 R 2 —, —C(O)—, —SO 2 —, —S(O)—, or —S—;
Y 1 , Y 3 and Y 4 are each independently N or CR 1 ;
L is a bond, —(CR 1 R 2 ) n —, —C(O)NR 3 —, —S(O) 2 —, —S(O) 2 NR 3 —, —S(O)—, —S(O)NR 3 —, —C(O)(CR 1 R 2 ) n O—, or —C(O)(CR 1 R 2 ) n —;
R is independently —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —C 5 -C 12 spirocycle, heterocyclyl, spiroheterocyclyl, aryl, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, spirocycle, heterocyclyl, spiroheterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, oxo, —NO 2 , —CN, —R 1 , —R 2 , —SR 3 , —OR 3 , —NHR 3 , —NR 3 R 4 , —S(O) 2 NR 3 R 4 , —S(O) 2 R 1 , —C(O)R 1 , —CO 2 R 1 , —NR 3 S(O) 2 R 1 , —S(O)R 1 , —S(O)NR 3 R 4 , —NR 3 S(O)R 1 , heterocycle, aryl, or heteroaryl;
R 1 and R 2 are independently, at each occurrence, —H, —R 3 , —R 4 , —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P and O, —OH, halogen, —NO 2 , —CN, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 , —S(O) 2 N(C 1 -C 6 alkyl) 2 , —N(C 1 -C 6 alkyl)S(O) 2 R 5 , —S(O) 2 (C 1 -C 6 alkyl), —(C 1 -C 6 alkyl)S(O) 2 R 5 , —C(O)C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)S(O) 2 C 1 -C 6 alkyl, or (CHR 5 ) n NR 3 R 4 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —OR 3 , —NHR 3 , NR 3 R 4 , —S(O) 2 N(R 3 ) 2 —, —S(O) 2 R 5 , —C(O)R 5 , —CO 2 R 5 , —NR 3 S(O) 2 R 5 , —S(O)R 5 , —S(O)NR 3 R 4 , —NR 3 S(O)R 5 , heterocycle, aryl, or heteroaryl;
or R 1 and R 2 can combine with the carbon atom to which they are both attached to form a cycloalkyl, heterocycle, spirocycle, spiroheterocycle, or spirocycloalkenyl;
or R 1 and R 2 , when on adjacent or non-adjacent atoms, can combine to form a heterocycle, cycloalkyl, aryl, heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P and O, or cycloalkenyl;
R 3 and R 4 are independently, at each occurrence, —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1-5 heteroatoms selected from N, S, P, and O, —S(O) 2 N(C 1 -C 6 alkyl) 2 , —S(O) 2 (C 1 -C 6 alkyl), —(C 1 -C 6 alkyl)S(O) 2 R 5 , —C(O)C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, or —(CHR 5 ) n N(C 1 -C 6 alkyl) 2 , wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more substituents selected from —OH, halogen, —NO 2 , oxo, —CN, —R 5 , —O(C 1 -C 6 )alkyl, —NH(C 1 -C 6 )alkyl, —N(C 1 -C 6 alkly) 2 , —S(O) 2 N(C 1 -C 6 alkyl) 2 , —S(O) 2 NHC 1 -C 6 alkyl, —C(O)C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)S(O) 2 C 1 -C 6 alkyl, —S(O)R 5 , —S(O)N(C 1 -C 6 alkyl) 2 , —N(C 1 -C 6 alkyl)S(O)R 5 , heterocycle, aryl, or heteroaryl;
R 5 is independently, at each occurrence, —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1-5 heteroatoms selected from N, S, P and O, —OH, halogen, —NO 2 , —CN, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 , —S(O) 2 NH(C 1 -C 6 alkyl), —S(O) 2 N(C 1 -C 6 alkyl) 2 , —S(O) 2 C 1 -C 6 alkyl, —C(O)C 1 -C 6 alkyl, —CO 2 C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)SO 2 C 1 -C 6 alkyl, —S(O)(C 1 -C 6 alkyl), —S(O)N(C 1 -C 6 alkyl) 2 , —N(C 1 -C 6 alkyl)S(O)(C 1 -C 6 alkyl) or —(CH 2 ) n N(C 1 -C 6 alkyl) 2 ;
n is an integer from 0 to 6; and
m is 0, 1, 2 or 3.

2. The compound of claim 1 , wherein X 4 is —C(O)—.

3. The compound of claim 1 , wherein m is 0 or 1.

4. The compound of claim 1 , wherein the compound is of the Formula I-a:

5. The compound of claim 1 , wherein the compound is of the Formula I-b:

6. The compound of claim 1 , wherein the compound is of the Formula I-c:

7. The compound of claim 1 , wherein the compound is of the Formula I-d:

8. The compound of claim 1 , wherein the compound is of the Formula I-e:

9. The compound of claim 1 , wherein the compound is of the Formula I-f:

10. The compound of claim 1 , wherein the compound is of the Formula I-g:

11. The compound of claim 1 , wherein the compound is of the Formula I-h:

12. The compound of claim 1 , wherein the compound is of the Formula I-j:

13. The compound of claim 1 , wherein the compound is of the Formula I-k:

14. The compound of claim 1 , wherein the compound is of the Formula I-m:

15. A compound of the Formula II:

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer or thereof, wherein:
X 1 is independently —CR 1 R 2 —, —NR 3 —, —O—, —SO 2 —, —S(O)—, or —S—;
X 2 , X 3 , X 4 , and X 7 are each independently —CR 1 R 2 —, —NR 3 —, —O—, —C(O)—, —SO 2 —, —S(O)—, or —S—;
X 5 and X 6 are each independently —CR 1 R 2 —, —C(O)—, —SO 2 —, —S(O)—, or —S—;
Y 1 , Y 3 and Y 4 are each independently N or CR 1 ;
L is a bond, —(CR 1 R 2 ) n —, —C(O)NR 3 —, —S(O) 2 —, —S(O) 2 NR 3 —, —S(O)—, —S(O)NR 3 —, —C(O)(CR 1 R 2 ) n O—, or —C(O)(CR 1 R 2 ) n —;
R is independently —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkenyl, —C 4 -C 8 cycloalkenyl, —C 2 -C 6 alkynyl, —C 3 -C 8 cycloalkyl, —C 5 -C 12 spirocycle, heterocyclyl, spiroheterocyclyl, aryl, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, wherein each -alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, spirocycle, heterocyclyl, spiroheterocyclyl, aryl, or heteroaryl is optionally substituted with one or more —OH, halogen, oxo, —NO 2 , —CN, —R 1 ,

Assignees

• Forma Therapeutics Inc

Inventors

• Ng Pui Yee
• Davis Heather
• Bair Kenneth W
• Millan David S
• Rudnitskaya Aleksandra
• Zheng Xiaozhang
• Han Bingsong
• Barczak Nicholas
• Lancia Jr David R

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07D491/107

  with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title

• C07D497/10

  Spiro-condensed systems · CPC title

• C07D405/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D221/20

  Spiro-condensed ring systems · CPC title